

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number  
**WO 2005/092325 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/345**,  
31/22, A61P 3/06

(21) International Application Number:  
PCT/IB2005/000733

(22) International Filing Date: 21 March 2005 (21.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/557,021 26 March 2004 (26.03.2004) US

(71) Applicant (for all designated States except US):  
**WARNER-LAMBERT COMPANY LLC** [US/US];  
201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOMAN, Reynold**


[US/US]; Pfizer Global Research and Development,  
2800 Plymouth Road, Ann Arbor, MI 48105 (US).  
**KARATHANASIS, Sotirios, Konstantinou** [GR/US];  
3476 Muirfield Way, Carmel, IN 46032 (US). **PANEK,**  
**Robert, Lee** [US/US]; Pfizer Global Research and De-  
velopment, 2800 Plymouth Road, Ann Arbor, MI 48105  
(US). **PARK, Tae-Sik** [KR/US]; Pfizer Global Research  
and Development, 2800 Plymouth Road, Ann Arbor, MI  
48105 (US). **REKHTER, Mark, David** [US/US]; 1874  
Limehouse Street, Carmel, IN 46032 (US).

(74) Agents: **FULLER, Grover, F., Jr.** et al.; Pfizer Inc., 201  
Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

[Continued on next page]

(54) Title: USE OF A SERINE PALMITOYLTRANSFERASE (SPT) INHIBITOR TO TREAT ATHEROSCLEROSIS AND DYS-  
LIPIDEMIA



(57) Abstract: The present invention relates to methods of treating atherosclerosis, dyslipidemia, other cardiovascular diseases and related diseases, such as diabetes, using a serine palmitoyltransferase (SPT) inhibitor. The present invention also relates to pharmaceutical compositions and kits that comprise a serine palmitoyltransferase (SPT) inhibitor, optionally with another pharmaceutical agent.

WO 2005/092325 A1



MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*